Furthermore, another study on cervical cancer patients revealed that the tolerable response rate for anti-PD-1/PD-L1 monotherapy varied from 8.8% to 26.3%, with the highest rate associated with tumor cells with PD-L1 overexpression (100, 130, 131). This evidence concerns the gene PDCD1 and neoplasm.